Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.85 ▼ -0.50
(-11.49%)
MKT CAP: $370.9M • VOL: 3.35M
52W L $3 52W H $7
ROARABLE / RQD
E • 29/100
PIOTROSKI
2 / 9
ZURA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$75.2M | -$55.2M | -$62.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$68.7M | -$52.4M | -$60.4M |
| EBITDA (Normalized) | -$75.2M | -$55.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$64.8M | -$28.1M | -$15.1M |
| Capital Expenditures (CapEx) | $113.0K | $75.0K | — |
| Free Cash Flow (FCF) | -$64.9M | -$28.2M | -$15.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $109.4M | $176.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $101.5M | $146.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZURA.